Castleview Partners LLC Acquires New Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Castleview Partners LLC acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,465 shares of the company’s stock, valued at approximately $45,000.

A number of other hedge funds have also added to or reduced their stakes in CRDF. Rhumbline Advisers increased its stake in Cardiff Oncology by 24.0% in the fourth quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock valued at $231,000 after acquiring an additional 10,290 shares during the last quarter. Callan Capital LLC increased its stake in Cardiff Oncology by 11.1% in the fourth quarter. Callan Capital LLC now owns 101,575 shares of the company’s stock valued at $441,000 after acquiring an additional 10,108 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Cardiff Oncology by 68.7% during the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock worth $1,253,000 after buying an additional 117,514 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Cardiff Oncology during the fourth quarter worth $56,000. Finally, HighTower Advisors LLC grew its stake in shares of Cardiff Oncology by 123.1% during the fourth quarter. HighTower Advisors LLC now owns 34,213 shares of the company’s stock worth $148,000 after buying an additional 18,880 shares during the last quarter. 16.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Cardiff Oncology in a research note on Wednesday. HC Wainwright boosted their target price on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, May 9th.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $3.10 on Friday. The stock has a market cap of $206.24 million, a PE ratio of -3.37 and a beta of 1.61. The firm’s fifty day moving average price is $3.09 and its two-hundred day moving average price is $3.55. Cardiff Oncology, Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative return on equity of 76.45% and a negative net margin of 8,308.50%. As a group, sell-side analysts predict that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.